Drugs that contain Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate
1. Adderall 10 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 10 before it's drug patent expiration?
More Information on Dosage
ADDERALL 10 family patents
2. Adderall 12.5 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 12.5 before it's drug patent expiration?
More Information on Dosage
ADDERALL 12.5 family patents
3. Adderall 15 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 15 before it's drug patent expiration?
More Information on Dosage
ADDERALL 15 family patents
4. Adderall 20 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 20 before it's drug patent expiration?
More Information on Dosage
ADDERALL 20 family patents
5. Adderall 30 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 30 before it's drug patent expiration?
More Information on Dosage
ADDERALL 30 family patents
6. Adderall 5 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 5 before it's drug patent expiration?
More Information on Dosage
ADDERALL 5 family patents
7. Adderall 7.5 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 7.5 before it's drug patent expiration?
More Information on Dosage
ADDERALL 7.5 family patents
8. Adderall Xr 10 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ADDERALL XR 10 before it's drug patent expiration?
More Information on Dosage
ADDERALL XR 10 family patents
9. Adderall Xr 15 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ADDERALL XR 15 before it's drug patent expiration?
More Information on Dosage
ADDERALL XR 15 family patents
10. Adderall Xr 20 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ADDERALL XR 20 before it's drug patent expiration?
More Information on Dosage
ADDERALL XR 20 family patents
11. Adderall Xr 25 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ADDERALL XR 25 before it's drug patent expiration?
More Information on Dosage
ADDERALL XR 25 family patents
12. Adderall Xr 30 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ADDERALL XR 30 before it's drug patent expiration?
More Information on Dosage
ADDERALL XR 30 family patents
13. Adderall Xr 5 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ADDERALL XR 5 before it's drug patent expiration?
More Information on Dosage
ADDERALL XR 5 family patents
14. Mydayis patents expiration
MYDAYIS Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6913768 | TAKEDA PHARMS USA | Sustained release delivery of amphetamine salts |
May, 2023
(11 months ago) | |
| US9173857 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
May, 2026
(2 years from now) | |
| US8846100 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
Aug, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 20, 2020 |
| Pediatric Exclusivity(PED) | Mar 13, 2023 |
| M(M-248) | Sep 13, 2022 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of MYDAYIS before it's drug patent expiration?
More Information on Dosage
MYDAYIS family patents